The Impact of the Mainstreaming Addiction Treatment Act and Associated Legislative Action on Pharmacy Practice.

The recent passage of the Mainstreaming Addiction Treatment (MAT) Act will expand access to treatment for opioid use disorder by eliminating prescriber registration requirements introduced as part of the Drug Abuse Treatment Act (DATA) of 2000. Without the X-Waiver, any Drug Enforcement Administration (DEA) registered prescriber can now prescribe buprenorphine. Eliminating DATA-2000 registration is the first step in improving access to buprenorphine, but additional barriers, including unclear restrictions on wholesale buprenorphine supply and insurance coverage, remain. Recently, the DEA formally clarified that suspicious order monitoring programs were managed entirely by wholesalers and manufacturers and that DEA does not set suspicious order monitoring limits. In this commentary, we address the somewhat conflicting implications of the MAT act and recent DEA guidance on buprenorphine dispensing in community pharmacy. We also discuss innovative practice models that leverage pharmacists' cognitive skills to manage pharmacotherapy for persons with opioid use disorder. Recent policy changes and emerging evidence suggest that pharmacists are better positioned than ever to provide low-barrier access to treatment for opioid use disorder and to show their value in this practice area by actively engaging patients prescribed buprenorphine.